Get access

A new large-scale manufacturing platform for complex biopharmaceuticals

Authors

  • Jens H. Vogel,

    Corresponding author
    1. Bayer Healthcare, Global Biological Development, 800 Dwight Way, Berkeley, California; telephone: 510-705-5000; fax: 510-705-4996
    Current affiliation:
    1. Boehringer Ingelheim, Fremont, CA.
    • Bayer Healthcare, Global Biological Development, 800 Dwight Way, Berkeley, California; telephone: 510-705-5000; fax: 510-705-4996
    Search for more papers by this author
  • Huong Nguyen,

    1. Bayer Healthcare, Global Biological Development, 800 Dwight Way, Berkeley, California; telephone: 510-705-5000; fax: 510-705-4996
    Search for more papers by this author
  • Roberto Giovannini,

    1. Bayer Healthcare, Global Biological Development, 800 Dwight Way, Berkeley, California; telephone: 510-705-5000; fax: 510-705-4996
    Current affiliation:
    1. Glenmark Pharmaceuticals, Switzerland.
    Search for more papers by this author
  • Jolene Ignowski,

    1. Bayer Healthcare, Global Biological Development, 800 Dwight Way, Berkeley, California; telephone: 510-705-5000; fax: 510-705-4996
    Search for more papers by this author
  • Steve Garger,

    1. Bayer Healthcare, Global Biological Development, 800 Dwight Way, Berkeley, California; telephone: 510-705-5000; fax: 510-705-4996
    Search for more papers by this author
  • Anil Salgotra,

    1. Bayer Healthcare, Global Biological Development, 800 Dwight Way, Berkeley, California; telephone: 510-705-5000; fax: 510-705-4996
    Search for more papers by this author
  • Jennifer Tom

    1. Bayer Healthcare, Global Biological Development, 800 Dwight Way, Berkeley, California; telephone: 510-705-5000; fax: 510-705-4996
    Search for more papers by this author

Abstract

Complex biopharmaceuticals, such as recombinant blood coagulation factors, are addressing critical medical needs and represent a growing multibillion-dollar market. For commercial manufacturing of such, sometimes inherently unstable, molecules it is important to minimize product residence time in non-ideal milieu in order to obtain acceptable yields and consistently high product quality. Continuous perfusion cell culture allows minimization of residence time in the bioreactor, but also brings unique challenges in product recovery, which requires innovative solutions. In order to maximize yield, process efficiency, facility and equipment utilization, we have developed, scaled-up and successfully implemented a new integrated manufacturing platform in commercial scale. This platform consists of a (semi-)continuous cell separation process based on a disposable flow path and integrated with the upstream perfusion operation, followed by membrane chromatography on large-scale adsorber capsules in rapid cycling mode. Implementation of the platform at commercial scale for a new product candidate led to a yield improvement of 40% compared to the conventional process technology, while product quality has been shown to be more consistently high. Over 1,000,000 L of cell culture harvest have been processed with 100% success rate to date, demonstrating the robustness of the new platform process in GMP manufacturing. While membrane chromatography is well established for polishing in flow-through mode, this is its first commercial-scale application for bind/elute chromatography in the biopharmaceutical industry and demonstrates its potential in particular for manufacturing of potent, low-dose biopharmaceuticals. Biotechnol. Bioeng. 2012; 109: 3049–3058. © 2012 Wiley Periodicals, Inc.

Get access to the full text of this article

Ancillary